Oral Candidiasis
Conditions
Interventions
SOWATER Antibacterial Solution Mouth Wash:Gargle SOWATER Antibacterial Solution Mouth Wash five times a day for one minute each time
SOWATER Mucosa Oral Disinfectant:Gargle SOWATER Mucosa Oral Disinfectant five times a day for one minute each time
Nystatin combination with SOWATER Antibacterial Solution Mouth Wash:Gargle SOWATER Antibacterial Solution Mouth Wash five times a day for one minute each time, and nystatin for one tablet three times
Nystatin combination with sodium bicarbonate mouthwash:Nystatin combination and sodium bicarbonate mouthwash
Gargle sodium bicarbonate mouthwash three times a day for one minute each time, and nystati
Sponsors
Peking University School and Hospital of Stomatology
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. No gender restrictions, aged > 18 years; 2. Clinically diagnosed with erythematous oral candidiasis; 3. Positive fungal microscopic examination or positive fungal culture; 4. Female subjects of childbearing age are screened with a negative pregnancy test and voluntarily take contraceptive measures throughout the trial; 5. The subjects participated voluntarily and signed the written informed consent.
Exclusion criteria
Exclusion criteria: 1. Clinically proven to suffer from other systemic mycosis; 2. Those who are known to have a history of allergy to the test drug, cannot tolerate it, or have an allergic constitution; 3. Lactating patients; 4. Those with mental disorders who cannot cooperate well and cannot evaluate changes regularly; 5. Patients with hepatic insufficiency (ALT, AST or TBIL>1.5 times the upper limit of the normal reference value), or patients with clinical manifestations of liver disease within two months before the implementation; 6. Patients with renal insufficiency (CR>1.5 times the upper limit of the normal reference value); 7. Patients with cardiac insufficiency (such as those with ischemic heart failure or a history of congestive heart failure); 8. Those with hematopoietic system diseases; 9. Those who have received other systemic antifungal drugs within 30 days before treatment or received local antifungal drug treatment within 2 weeks; 10. Patients with chronic mucocutaneous candidiasis (CMCC); 11. HIV positive patients; 12. Patients who are clinically proven to have related diseases that affect oral saliva secretion or are taking drugs that affect saliva secretion; 13. Those who have participated in other clinical trials within the past month.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Classification of oral pain/burning sensation;Atrophic erythema classification of oral mucosa;The quantity of salivary Candida; | — |
Secondary
| Measure | Time frame |
|---|---|
| taste assessment; | — |
Countries
China
Contacts
Public ContactPeiru Zhou
Peking University School and Hospital of Stomatology
Outcome results
None listed